In November 2020, Human Link published a study describing an “immunomodulatory herbal extract with potent antiviral activity against SARS-CoV-2” called EGYVIR. The research was funded by National Institute of Allergy and Infectious Diseases (NIAID).1)
Human Link's partners include:2)